Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Silo Pharma, Inc. on January 15, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "SILO".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance.
Material Changes and Events
Under Item 8.01 (Other Events), the Company reported the successful transmission to the United States Patent and Trademark Office (USPTO) of its United States national phase entries for three Patent Cooperation Treaty (PCT) applications originally filed in July 2021. These applications concern the use of central nervous system-homing peptides for delivering anti-inflammatory therapeutics coupled with psilocybin to the central nervous system.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, specific risks, or contingencies beyond the patent filing event.
Key Facts for Investor Verification
- Confirmation of the USPTO acceptance of the three PCT national phase entries.
- Details regarding the specific scope and claims of the patents related to psilocybin delivery systems.
- Timeline for potential patent issuance and its impact on the company's intellectual property portfolio.